Month Three · October 31, 2026
Enduring Internet Activities
1.75 CME / CE Credits
From Cholesterol to Dyslipidemia
Treatment Strategies and Targets
October 31, 2026 – April 30, 2027
This month
1.75 credits
Across two activities
Claim credit by May 30, 2027
Two Activities This Month
Choose where to start
Webinar
1.25 CME / CE Credits
Goals Are Back! LDL-C, Non-HDL-C, and ApoB in Clinical Practice: Webinar
Review new lipid treatment targets, statin initiation thresholds, treatment goals in primary and secondary prevention, intensification strategies, and multidisciplinary dyslipidemia management.
Michael J. Wilkinson
MD, FNLA
Seth S. Martin
MD, MHS
Podcast
0.5 CME / CE Credit
Achieving Lipid Goals: From Clinical Strategy to Real-World Practice: Podcast
A companion discussion of lipid treatment targets, statin initiation, primary and secondary prevention goals, treatment intensification, and multidisciplinary care.
Mary Katherine Cheeley
PharmD, BCPS, CLS, FNLA
Eugenia Gianos
MD, FNLA
Educational Objectives
What you’ll be able to do
Upon successful completion of the activities in Month Three, participants should be better able to:
1
Review new lipid treatment targets.
2
Determine appropriate statin initiation thresholds.
3
Apply treatment goals in primary and secondary prevention.
4
Review intensification strategies.
5
Implement dyslipidemia management in multidisciplinary care.
Faculty
Month Three Faculty
Webinar Faculty
Michael J. Wilkinson
MD, FNLA
Webinar Faculty
Seth S. Martin
MD, MHS
Podcast Faculty
Mary Katherine Cheeley
PharmD, BCPS, CLS, FNLA
Podcast Faculty
Eugenia Gianos
MD, FNLA
Accreditation & Disclosures
Activity front matter
Each activity is separately accredited. The sections below apply to both the webinar and the podcast; credit designation and disclosures are listed separately for each.
Program Overview & Target Audience
Given the breadth and complexity of the 2026 dyslipidemia guidelines, and the well-documented gaps in risk stratification, primary prevention practice, treatment goal attainment, non-statin utilization, and population-specific management, there is a clear and urgent need for education that facilitates translation into clinical practice. Clinicians must not only understand the updated recommendations but also develop the competence and confidence to apply them across diverse patient populations and care settings.
By aligning educational content with documented practice gaps and delivering it in a format that supports sustained engagement, the program aims to improve clinician performance and ultimately enhance patient outcomes. Increased adoption of guideline-recommended practices has the potential to improve lipid control, reduce ASCVD events, and address persistent disparities in cardiovascular care.
Target Audience
This activity was designed for clinicians involved in ASCVD risk assessment and lipid management (physicians, pharmacists, advanced practice providers in primary care, dietitians, cardiology, endocrinology, and internal medicine).
Type of Activity
Enduring Internet Activity
Criteria for Success & Commercial Support
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at lipid.org/cme. The deadline to claim credit is May 30, 2027. Questions related to this content should be sent to cme@lipid.org.
Commercial Support
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation, Merck & Co., Inc., and Amgen Inc.
Webinar — Credit Designation & Disclosures 1.25 Credits
CME/CE credit provided by the National Lipid Association
In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this live internet activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Pharmacist Accreditation Statement
Universal Activity Number UAN JA0007192-0000-26-035-H01-P (Knowledge)
This Activity has been approved for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education
Nursing Accreditation Statement
The maximum number of hours awarded for this CE activity is 1.25 contact hours.
Dietitians
Completion of this activity awards 1.25 continuing professional education units (CPEUs) for Registered Dietitians (RD) and Dietetic Technicians (DTR). RDs and DTRs should select activity type 102 in their Activity Logs.
Disclosure Information — Faculty, Planners & Reviewers
| Dave L. Dixon, PharmD, FNLA, CLS | Consultant – Innovation Horizons |
| Kaye-Eileen Willard, MD, FNLA | Has nothing to disclose. |
| Michael J. Wilkinson, MD | Investigator – Amgen, Esperion Consultant – Regeneron, Kaneka, New Amsterdam, Amarin, Ionis Advisory Board – Novartis, New Amsterdam, Ionis Institutional Researcher – Novartis |
| Seth S. Martin, MD, MHS | Consultant – Amgen, Heartflow, Merck, Novartis, Regeneron, Kaneka |
| NLA Staff | Has nothing to disclose. |
| Susan Halli Demeter, DNP | Has nothing to disclose. |
Podcast — Credit Designation & Disclosures 0.5 Credit
CME/CE credit provided by the National Lipid Association
In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this live internet activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Pharmacist Accreditation Statement
Universal Activity Number UAN JA0007192-0000-26-036-H01-P (Knowledge)
This Activity has been approved for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education
Nursing Accreditation Statement
The maximum number of hours awarded for this CE activity is 0.5 contact hours.
Dietitians
Completion of this activity awards 0.5 continuing professional education units (CPEUs) for Registered Dietitians (RD) and Dietetic Technicians (DTR). RDs and DTRs should select activity type 102 in their Activity Logs.
Disclosure Information — Faculty, Planners & Reviewers
| Dave L. Dixon, PharmD, FNLA, CLS | Consultant – Innovation Horizons |
| Kaye-Eileen Willard, MD, FNLA | Has nothing to disclose. |
| Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA | Consultant – Novartis, Regeneron |
| Eugenia Gianos, MD, FNLA | Investigator – Amgen, Eli Lilly and Company, Novartis |
| NLA Staff | Has nothing to disclose. |
Disclaimers, Unlabeled Use & Permissions
Disclosure of Unlabeled Use and Investigational Products
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure Declaration
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Permissions
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
next up: Non-Statin Therapies and Emerging Treatments
Month Four releases November 30, 2026 — Adding non-statins and navigating access. Complete Month Three while it is open through May 30, 2027.